The product is indicated for luteal phase support in induced cycles, e.g., in vitro fertilization cycles. Progesterone is needed to increase endometrial receptivity for implantation of an embryo. Once an embryo is implanted, progesterone acts to maintain the pregnancy. Crinone is a bioadhesive gel containing micronized progesterone. The pharmacokinetics of progesterone from Crinone gel are rate-limited by absorption.
Absorption is prolonged, due to the bioadhesive and sustained-release properties of the gel.
The bioavailability of progesterone from Crinone vaginal gel is comparable to that of a progesterone vaginal capsule, but is more than 20 times higher than that of a progesterone oral capsule. Most women respond to once-daily therapy. If pregnancy occurs, treatment may be continued for up to 10-12 weeks. Progesterone has not been proven beneficial in preventing miscarriage in women with a history of recurrent spontaneous abortion.